Kodu・Aktsiate loetelu・Beam Therapeutics Inc

Beam Therapeutics Inc

Avatud

SektorTervishoid

26.84 -4.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.91

Max

28.15

Põhinäitajad
By Trading Economics
Sissetulek	-339M -94M
Müük	-82M 32M
Aktsiakasum	-0.91
Kasumimarginaal	-297.177
Töötajad	522
EBITDA	-349M -89M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+112.27% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-511M 2.6B
Eelmine avamishind	31.29
Eelmine sulgemishind	26.84

Uudiste sentiment

By Acuity

93%

3 / 340 Pingereas Healthcare

Beam Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 19:16 UTC

Correlated Moves

News

Beam Therapeutics is rising amid a broader market rally, with a market cap of $2.64 billion and $1.2 billion in liquidity to support operations.

31. juuli 2026, 19:16 UTC

Correlated Moves

Beam Therapeutics shares are lower, reflecting a decline in first-quarter results and broader sector weakness. The stock remains near the lower end of its one-month range.

30. juuli 2026, 23:06 UTC

Beam Therapeutics Inc shares are higher in after-hours trading, advancing since Thursday's close, despite remaining below the 20-day moving average.

29. juuli 2026, 22:51 UTC

Beam Therapeutics shares are lower in after-market hours following a volatile session, amid broader market uncertainty after the Federal Reserve's interest rate decision.

28. juuli 2026, 23:51 UTC

Beam Therapeutics Inc shares are lower in after-market trading, experiencing unusual volatility amid broader market declines and positioned below its 20-day moving average.

27. juuli 2026, 23:06 UTC

Beam Therapeutics Inc shares are higher in after-market hours, despite a broader decline in trading. No specific news was identified to explain the increase.

24. juuli 2026, 19:26 UTC

Event

Correlated Moves

Beam Therapeutics is declining today, reflecting broader market trends, with the Russell 2000 Index down. The stock remains below its 20-day moving average.

23. juuli 2026, 09:51 UTC

News

Beam Therapeutics is higher in pre-market trading, driven by significant upcoming clinical milestones, including the global BEAM-302 trial and an FDA application for risto-cel.

22. juuli 2026, 23:46 UTC

Beam Therapeutics shares higher in after-market trading, advancing since Wednesday's close. The stock remains below its 20-day moving average amid broader market influences.

21. juuli 2026, 18:06 UTC

Correlated Moves

Beam Therapeutics shares are higher today, reflecting positive sentiment in small-cap stocks amid anticipation of upcoming earnings results from major companies.

20. juuli 2026, 23:56 UTC

Beam Therapeutics Inc is higher in after-market trading, showing notable strength since Monday's close. No specific news was identified to explain the movement.

Võrdlus sarnastega

Hinnamuutus

Beam Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

112.27% tõus

12 kuu keskmine prognoos

Keskmine 55 USD 112.27%

Kõrge 80 USD

Madal 26 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Beam Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi Beam Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

3 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.